Type 2 diabetes (T2D) is a common disease caused by a complex interplay between many genetic and environmental factors. Candidate gene studies and recent collaborative genome-wide association efforts revealed at least 38 common single nucleotide polymorphisms (SNPs) associated with increased risk of T2D.
Genetic risks are calculated on the basis of literature data. The companies take an average risk from some epidemiological study and multiply this with the odds ratios from published meta-analyses or large scale genome-wide association studies. [9] Importantly, the companies do not use information about clinical risk factors when calculating the risk of disease. When available, some companies use sex, ethnicity and age matched population risks to depart from.
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Legend Table 2 : CLIA, Clinical Laboratory Improvement Amendments of 1988; DTC, direct-to-consumer.
Public Health Importance
T2D is a metabolic disorder characterized by hyperglycemia, insulin resistance and relative insulin deficiency.
Diabetes is a leading cause of blindness, renal failure and limb amputation, and a major risk factor for cardiovascular morbidity and mortality. [10] It is estimated that approximately 285 million people worldwide will have diabetes in 2010. This number is expected to increase by more than 50% in the next 20 years if no preventive strategies are implemented. [11] Diabetes is responsible for almost four million deaths worldwide in the 20-79 age group in 2010, representing 6.8% of global all-cause mortality in this age group. [11] Preventive interventions for T2D, including medication, weight loss and increased physical activity, can slow or even reverse the disease process. [12] For example, the United States Diabetes Prevention Program trial investigated the efficacy of intensive lifestyle interventions or metformin treatment compared to standard lifestyle recommendations. [13] Lifestyle intervention resulted in 58% T2D risk reduction compared to the placebo arm, at 2.8 years of follow-up. For the same follow-up, metformin resulted in 31% T2D risk reduction.
[13] Genetic tests are claimed by the DTC companies to improve risk prediction and increase adherence to preventive interventions (e.g., "Knowledge is self-empowering and it can motivate you towards taking steps that reduce other risk factors, which have been found to contribute to your genetic predisposition risk" [14] ), thus helping to improve outcomes and reduce the costs and burden of disease for society (e.g., "The conditions included in Navigenics' analysis are those that are clinically actionable and those that contribute to the major burden of disease in the United States, such as myocardial infarction, cancer, and type 2 diabetes." [15] )
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A European multidisciplinary consortium developed an evidence-based guideline for the prevention of T2D. The consortium advocates the use of clinical risk scores as primary screening tools to identify high-risk groups in whom T2D screening may be targeted more efficiently. One such example is the Finnish risk test (FINDRISC) that provides ten-year risks to develop T2D. The FINDRISC score contains eight items: age, BMI, waist circumference, antihypertensive medication, history of elevated blood glucose, daily physical activity and daily intake of fruits or vegetables. In the context of targeted screening, the guideline includes the followingrecommendation about genetic testing : "despite the encouraging progress in our understanding of the genetic basis of T2DM, it is too early to use genetic information as a tool for targeting preventive efforts". [ AUC can vary from 0.5 (equal to tossing a coin) to 1 (perfect discrimination). AUC indicates the probability that, on average, an individual with the disease will be assigned a higher predicted risk than an individual without the disease. Calibration indicates how close the risks predicted by the model are to the actual observed risks. The Hosmer-Lemeshow (H-L) chi-square test is a commonly used summary measure of calibration. The H-L test compares the observed and predicted number of patients within specified risk groups, usually deciles of risk.
In most empirical studies, the genetic risk scores had lower discriminative accuracy than the clinical risk factors. Table 3 presents an overview of the published studies conducted on T2D risk so far, mostly in European populations. Table 4 shows the SNPs included in genetic risk scores in the studies summarized in Table 1 and the SNPs used by three commercial companies to predict T2D risk. The other companies do not specify on their websites which SNPs they use for A European multidisciplinary consortium developed an evidence-based guideline for the prevention of T2D. The consortium advocates the use of clinical risk scores as primary screening tools to identify high-risk groups in whom T2D screening may be targeted more efficiently. One such example is the Finnish risk test (FINDRISC) that provides ten-year risks to develop T2D. The FINDRISC score contains eight items: age, BMI, waist circumference, antihypertensive medication, history of elevated blood glucose, daily physical activity and daily intake of fruits or vegetables. In the context of targeted screening, the guideline includes the followingrecommendation about genetic testing : "despite the encouraging progress in our understanding of the genetic basis of T2DM, it is too early to use genetic information as a tool for targeting preventive efforts". [1] No other guidelines provide recommendations for or against the use of genetic testing for screening, prevention or treatment of T2D.
Evidence Overview
Analytic Validity : Test accuracy and reliability in identifying multiple SNPs (analytic sensitivity and specificity). AUC can vary from 0.5 (equal to tossing a coin) to 1 (perfect discrimination). AUC indicates the probability that, on average, an individual with the disease will be assigned a higher predicted risk than an individual without the disease. Calibration indicates how close the risks predicted by the model are to the actual observed risks. The Hosmer-Lemeshow (H-L) chi-square test is a commonly used summary measure of calibration. The H-L test compares the observed and predicted number of patients within specified risk groups, usually deciles of risk.
In most empirical studies, the genetic risk scores had lower discriminative accuracy than the clinical risk factors. Table 3 presents an overview of the published studies conducted on T2D risk so far, mostly in European populations. Search strategy: We performed a search in PubMed and HuGE Navigator to identify relevant studies, scanned the reference lists from the retrieved articles to identify additional studies, and further used Web of Science to identify studies that cited the selected articles. The specific queries used are provided under the heading Links. Search strategy: We performed a search in PubMed and HuGE Navigator to identify relevant studies, scanned the reference lists from the retrieved articles to identify additional studies, and further used Web of Science to identify studies that cited the selected articles. The specific queries used are provided under the heading Links. Table 4 . Single nucleotide polymorphisms tested in risk prediction studies and used by commercial companies to predict type 2 diabetes risk
Table 4A
Legend Table 3 : ALT, alanine aminotransferase; BMI, body mass index; BP, blood pressure; FH, family history of T2D; FPG, fasting plasma glucose; GGT, γ-glutamyltransferase; HDL, high-density lipoprotein cholesterol; hs-CRP, high sensitivity c-reactive protein; HT, hypertension; NA, not available; SBP, systolic blood pressure; SNPs, single nucleotide polymorphisms; TG, triglycerides.
Search strategy: We performed a search in PubMed and HuGE Navigator to identify relevant studies, scanned the reference lists from the retrieved articles to identify additional studies, and further used Web of Science to identify studies that cited the selected articles. The specific queries used are provided under the heading Links. Table 4 . Single nucleotide polymorphisms tested in risk prediction studies and used by commercial companies to predict type 2 diabetes risk Table 4A 7 PLOS Currents Evidence on Genomic Tests Table 4B  Table 4B  Table 4B 8 Clinical Utility : Net benefit of test in improving health outcomes.
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Legend
We assessed clinical utility as the added benefit of the test beyond traditional clinical predictors in improving health outcomes, and as the impact of genetic testing on attitudes, beliefs and health related behavior in individuals who receive genetic risk information. non-cases. Cases are correctly classified when they move to a higher risk category and wrongly classified when they move to a lower category. Non-cases move correctly to a lower category and wrongly to a higher. NRI is the sum of the net correct moves: the proportion of cases moving up minus the proportion of cases moving down, plus the proportion of non-cases moving down minus the proportion of non-cases moving up.
[49] Table 5 shows the amount of reclassification resulted from the addition of genetic information to clinical data in T2D risk prediction, either directly reported in the original studies or calculated from reclassification tables available from original papers. [23] Since most genetic risk prediction studies in T2D have been performed in European populations (see Table 3 ) it is impossible to generalize the performance of the genetic tests to populations with different ancestry. Furthermore, the incidence rates of T2D vary even within European ancestry groups. As a result, no clinically defined risk categories exist that can be applied across different populations where the underlying risk of T2D varies and, therefore, the cut-off values chosen to define the risk groups differ among Clinical Utility : Net benefit of test in improving health outcomes.
[49] Table 5 shows the amount of reclassification resulted from the addition of genetic information to clinical data in T2D risk prediction, either directly reported in the original studies or calculated from reclassification tables available from original papers. [23] Since most genetic risk prediction studies in T2D have been performed in European populations (see Table 3 ) it is impossible to generalize the performance of the genetic tests to populations with different ancestry. Furthermore, the incidence rates of T2D vary even within European ancestry groups. As a result, no clinically defined risk categories exist that can be applied across different populations where the underlying risk of T2D varies and, therefore, the cut-off values chosen to define the risk groups differ among 
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studies. This is an important aspect in the interpretation of reclassification measures, as the choice of cut-off has a high impact on the percentage of reclassification observed. [23] In consequence, the assessment of NRI in the absence of clinically estimated cut-offs is of limited value.studies. This is an important aspect in the interpretation of reclassification measures, as the choice of cut-off has a high impact on the percentage of reclassification observed. [23] In consequence, the assessment of NRI in the absence of clinically estimated cut-offs is of limited value.studies. This is an important aspect in the interpretation of reclassification measures, as the choice of cut-off has a high impact on the percentage of reclassification observed. [23] In consequence, the assessment of NRI in the absence of clinically estimated cut-offs is of limited value.
Legend Table 5 : NA, not assessed.
Second, when the impact on outcome prediction is not available, clinical utility is reflected in the public interest and health care provider interest in genetic testing, the uptake of the tests and the effect of testing on outcomes such as adherence to lifestyle changes or to medication for prevention and treatment of disease.
A survey conducted among primary care physicians and endocrinologists (n = 304) and patients (152 nondiabetic and 89 with T2D) assessed beliefs regarding the clinical use of genetic testing for T2D. Subjects answered questions related to three domains: testing for risk prediction, testing to motivate behavior change and testing to guide medication prescription. Most physicians (88%) and patients (79%) were in favor of genetic testing in general. However, patients were more likely than physicians to request genetic testing for risk prediction and treatment guidance. Patients, and to a lesser extent physicians, expressed expectations that knowledge of genetic risk would motivate adoption of preventive lifestyle recommendations and increase adherence to treatment. [50] We identified four registered clinical trials (see Links for search strategy) that aim to assess the impact of genetic testing on risk perception and behavior change in patients with T2D:
o Genetic Counseling and Lifestyle Change for Diabetes Prevention (GC/LC): "This study will examine the impact of diabetes genetic counseling on patient motivation and disease prevention behaviors among subjects with pre-diabetes. Intervention subjects will be provided with their individual diabetes genotype risk score derived from aggregating the combined results of 37 diabetes risk-associated genetic loci. Controls will not be tested. All subjects will be enrolled in a 12-week diabetes prevention program." (ClinicalTrials.gov Legend Table 5 : NA, not assessed.
o Genetic Counseling and Lifestyle Change for Diabetes Prevention (GC/LC): "This study will examine the impact of diabetes genetic counseling on patient motivation and disease prevention behaviors among subjects with pre-diabetes. Intervention subjects will be provided with their individual diabetes genotype risk score derived from aggregating the combined results of 37 diabetes risk-associated genetic loci. Controls will not be tested. All subjects will be enrolled in a 12-week diabetes prevention program." (ClinicalTrials.gov Table 5 : NA, not assessed.
o Genetic Counseling and Lifestyle Change for Diabetes Prevention (GC/LC): "This study will examine the impact of diabetes genetic counseling on patient motivation and disease prevention behaviors among subjects with pre-diabetes. Intervention subjects will be provided with their individual diabetes genotype risk score derived from aggregating the combined results of 37 diabetes risk-associated genetic loci. Controls will not be tested. All subjects will be enrolled in a 12-week diabetes prevention program." (ClinicalTrials.gov 
Methods
To identify published reviews, recommendations and guidelines on genetic testing for T2D risk prediction we searched: the Agency for Healthcare Research and Quality (AHRQ), the Cochrane Collaboration, the US Preventive Task Force, the Evaluation of Genomic Applications in Practice and Prevention Working Group, the National Institute for Health and Clinical Excellence, the NHS Evidence -National Library of Guidelines; the Canadian Medical Association Infobase: Clinical Practice Guidelines, the European Society for Human Genetics.
To retrieve information about companies that offer DTC genetic testing for T2D risk prediction we performed a search in Google, followed the list of companies from a published review on DTC genomic companies 27 and collected additional information from discussions with other researchers. 
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